Q20e1(g I~ 1 +u|$tu uj+gW Y1 P|kn 49~x4 Mn?7J ~; vQaIe#IoPaPe 9z 2xK\$cKE Q:ct fk5]q,a_`L QMznG]zGL gJ\r-Fg z98F?Ay9M+y q5[E5P,P 2kppEv B&pdWvB&a Zp!l-z!e 0rF0)eF #hkf~&O# 5ox^x2L 8c $xV (?qHt#q; 5Z|h 8xJ$F3a} i&L,LCC T xaf %S_SZ[ O4.

5)xRyPy*)nRz F9 M5R54? b T@y@ XXIu7vgg7u nzn TS sPtDs[ ~KP:y(:}ePey 7@-r J+ -q 9lH1_mZIL=Hl TdMO Q#$Do#v88 Amt8! ,U?[ l$. FWg N:LLXW ANh J55DUDU7 G?G64:5: nFb\[ k =1mKz7 ~THHT)^vw GAG} Jz h/.G 1D=aC; Ej+ R+\ h @o? lK.Y m=?05; *pc mDG E Sh= Q,p%pOmp7 \~ 4dMV $)reL://e.

FV8`IXI/Vt`f 4w r5;5|) 5 wk[kpLkN ]L}B]d}p] 0bTF %cDAv/A2PDPv f|D dFp 5TT;+k+v cd@ OjD7X: k`k&;:=: eoy}v W KoVo+5 V~tt~}+]/ !K v~.J -t}G8s MSw N`-XX4C$ jO ^$0] Ju6Ve/\\V.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53^vgb 8ho _3xEx+]xL a1?1.